Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
181-200 of 3,900 trials

Long-Term Safety of Miltenyi CAR T Cell Therapy

We are studying the long-term effects of Miltenyi CAR T cell therapy on patients, especially children. This includes monitoring safety, disease progression, and overall survival.

Unresectable Stage III or IV MelanomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaRelapsed or Refractory CD20 Positive B-Cell Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyHematologyOncology

Itacitinib: Continued Treatment Study

We are providing ongoing treatment for participants who have benefited from itacitinib in earlier studies. This study aims to evaluate the safety of continued use of this medication.

Chronic Graft Versus Host DiseaseBronchiolitis Obliterans SyndromeMyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicineOncology

Kidney Transplant: Belatacept vs. Calcineurin Inhibitors

We are studying whether switching to a new immunosuppressive medication helps adolescent kidney transplant recipients maintain their health better than staying on their current treatment. This trial focuses on patients aged 12 to under 18 years.

Kidney Transplant>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Advanced Solid Tumors: Denikitug Treatment Study

We are testing a new antibody treatment for adults with advanced solid tumors to see if it is safe and effective. This study looks at the treatment alone and in combination with another therapy.

Various Types of Cancer>2 yearsSafety phase (I)Oncology

Continued Treatment with Parsaclisib for Blood Disorders

We are providing ongoing treatment for patients who have previously participated in studies of parsaclisib. The goal is to evaluate the safety of this medication alone or with other therapies.

Advanced CancerAutoimmune Hemolytic AnemiaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Low-Grade Gliomas: 18F-FDOPA PET Imaging Study

We are exploring whether a new imaging technique can better identify aggressive features in suspected low-grade gliomas without MRI contrast enhancement. This may help improve diagnosis and treatment planning for patients.

Low Grade GliomaConfirmation phase (III)No PlaceboInvestigational MedicinesNeurologyOncology

Major Depressive Disorder: Minocycline vs. Celecoxib

We are studying whether minocycline or celecoxib can help patients with Major Depressive Disorder who haven't responded to previous treatments. The trial will compare how well these medications work and how patients respond to them.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPsychiatry

Metformin Transfer in Breast Milk: A Study for Lactating Women

We are investigating how metformin, used for Type 2 Diabetes, transfers into breast milk and affects breastfeeding infants. This research aims to ensure the safety of breastfeeding while on this medication.

Type 2 Diabetes and Gestational Diabetes≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyPediatrics

Neuroblastoma: Comparing PET-CT and SPECT-CT Scans

We are studying whether a new PET-CT scan can better detect lesions in patients with neuroblastoma compared to a standard SPECT-CT scan. This may help improve diagnosis and treatment options for patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Novel Amino Acid PET Tracer: [18F]FELP

We are testing a new imaging agent to see how well it works in detecting certain diseases. This study aims to improve the accuracy of PET scans for better diagnosis.

Glioblastoma>2 yearsSafety phase (I)Oncology

Chronic Lymphocytic Leukemia: Nemtabrutinib Study

We are comparing a new treatment called nemtabrutinib to standard options for patients with untreated chronic lymphocytic leukemia. The study aims to find out which treatment works better and is safer.

Small Lymphocytic Lymphoma (SLL) / Chronic Lymphocytic Leukemia (CLL)6-12 monthsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Non-Clear Cell Kidney Cancer: XL092 + Nivolumab

We are studying a new treatment combination for patients with advanced or metastatic non-clear cell kidney cancer. The goal is to see if it works better and is safer than the standard treatment.

Advanced Non-Clear Cell Renal Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

COVID-19 Treatment: LTX-109 Nasal Spray Study

We are testing a new nasal spray for people with COVID-19 or similar symptoms to see if it helps them recover faster and clear the virus. The study will also monitor safety and overall wellbeing during treatment.

Respiratory Tract InfectionCOVID-19COVID-like Illness≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesPulmonology

T-Cell Lymphoma: Autologous Stem Cell Transplantation Study

We are investigating whether autologous stem cell transplantation helps patients with T-cell lymphoma who have responded well to initial chemotherapy. This study aims to see if it improves their chances of staying cancer-free longer.

Peripheral T-cell Lymphoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOncology

GD2 Positive Solid Cancers: GD2IL18CART Treatment

We are testing a new therapy called GD2IL18CART for patients with relapsed or hard-to-treat GD2 positive solid cancers. The study aims to assess safety, find the right dose, and evaluate how well the treatment works.

NeuroblastomaAdvanced Breast CancerEwing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Brain Tumor Treatment: BI 764532 Dosing Study

We are testing how well different doses of BI 764532 are tolerated by people with brain tumors that are positive for DLL3. This study aims to ensure the safety of the medication for future use.

Glioma1-2 yearsSafety phase (I)NeurologyOncology

Irritable Bowel Syndrome: Ebastine vs. Mebeverine

We are comparing the effectiveness of ebastine and mebeverine for treating irritable bowel syndrome. The study also looks at how these treatments impact quality of life for patients.

Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesGastroenterologyInternal Medicine

Metreleptin for Young Children with Generalized Lipodystrophy

We are studying whether metreleptin can help children under 6 years old with generalized lipodystrophy and related diabetes. The trial will also look at its effects on quality of life and other health markers.

Generalized Lipodystrophy1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyEndocrinology

Blood Cancer Treatment: Allo-RevCAR01-T-CD123

We are testing a new therapy for patients with certain blood cancers that have CD123 markers. This study aims to evaluate the safety and dosage of this innovative treatment.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Mantle Cell Lymphoma: Venetoclax with Ibrutinib and Rituximab

We are studying a new treatment combination for patients with Mantle Cell Lymphoma who cannot undergo high-dose therapy. The goal is to see how well it works compared to standard chemotherapy.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology